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Abstract
Traumatic brain injury (TBI) survivors often suffer from long-lasting cognitive impairment that stems from hippocampal
injury. Systemic administration of insulin-like growth factor-1 (IGF-1), a polypeptide growth factor known to play vital roles
in neuronal survival, has been shown to attenuate posttraumatic cognitive and motor dysfunction. However, its
neuroprotective effects in TBI have not been examined. To this end, moderate or severe contusion brain injury was induced
in mice with conditional (postnatal) overexpression of IGF-1 using the controlled cortical impact (CCI) injury model. CCI
brain injury produces robust reactive astrocytosis in regions of neuronal damage such as the hippocampus. We exploited
this regional astrocytosis by linking expression of hIGF-1 to the astrocyte-specific glial fibrillary acidic protein (GFAP)
promoter, effectively targeting IGF-1 delivery to vulnerable neurons. Following brain injury, IGF-1Tg mice exhibited a
progressive increase in hippocampal IGF-1 levels which was coupled with enhanced hippocampal reactive astrocytosis and
significantly greater GFAP levels relative to WT mice. IGF-1 overexpression stimulated Akt phosphorylation and reduced
acute (1 and 3d) hippocampal neurodegeneration, culminating in greater neuron survival at 10d after CCI injury.
Hippocampal neuroprotection achieved by IGF-1 overexpression was accompanied by improved motor and cognitive
function in brain-injured mice. These data provide strong support for the therapeutic efficacy of increased brain levels of
IGF-1 in the setting of TBI.
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Introduction
Traumatic brain injury (TBI) is one of the major causes of death
and disability worldwide. TBI survivors often experience cognitive
impairment suggestive of neuronal damage in areas controlling
learning and memory [1]. Hippocampal activity, critical for
acquisition and retrieval of short-term memory tasks [2,3], is
compromised after TBI. Experimental models of TBI recapitulate
learning and memory dysfunction as well as altered long term-
potentiation and cell loss in the hippocampus [4–8]. For example,
controlled cortical impact (CCI) brain injury results in spatial
memory impairment and neuronal damage in the cornu ammonis-
3 (CA-3), CA-1 and dentate gyrus subregions, the severity of which
can be controlled by altering the depth of impact [9,10].
Owing to their pluripotent actions in the central nervous system
(CNS), neurotrophic factors are considered potential therapeutic
agents for TBI [11]. Insulin-like growth factor-1 (IGF-1) is a 7.5-
kDa polypeptide hormone that in the CNS acts as a neurotrophic
factor, essential for neural cell differentiation, proliferation and
survival during development and adulthood. IGF-1 mediates its
anabolic effects through the IGF-1 receptor (IGF-1R) that is linked
to two major signaling pathways, PI3K/Akt and MAP kinase [12].
Studies suggest the PI3K/Akt pathway predominates in IGF-1
mediated neuroprotection [13–15]. In the adult brain IGF-1
expression is low compared to the developing brain and is mainly
present in neurons [16]. Endogenous levels of IGF-1 increase
transiently after TBI [17], but may be insufficient to sustain
damaged neurons. Although administration of exogenous IGF-1
confers neuroprotection in experimental models of ischemic brain
injury [18–21], its effectiveness in promoting cell survival after TBI
is largely unknown. Nonetheless, systemic administration of IGF-
1 as a potential therapy for TBI is supported by studies
demonstrating improved behavioral outcomes in rodent models
[22,23] and by clinical studies demonstrating improved nitrogen
balance in patients with severe TBI [24].
To determine the neuroprotective role of IGF-1 in TBI in the
absence of potential systemic effects, we used previously charac-
terized IGF-1 transgenic (IGF-1Tg) mice [25]. IGF-1 overexpres-
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sion was restricted to glial fibrillary acidic protein (GFAP)
expressing cells with transgene expression under the control of a
‘Tet-off’ system. The ‘Tet-off’ strategy allowed suppression of IGF-
1 overexpression during postnatal development by administration
of doxycycline. Because contusion TBI produces astrogliosis
accompanied by increased GFAP expression in regions of
neuronal damage, we postulated that GFAP-linked IGF-1
overexpression would effectively deliver IGF-1 to vulnerable brain
areas.
Utilizing a targeted IGF-1 delivery technique linking IGF-1
overexpression to regional posttraumatic reactive astrocytosis, we
show that following moderate or severe contusion brain injury,
astrocyte-derived IGF-1 exerts autocrine effects on astrocytes,
reduces regional hippocampal neurodegeneration and improves
post-traumatic cognitive and motor function.
Materials and Methods
Animals
To generate astrocyte-specific IGF-1 transgenic mice with
conditional overexpression, heterozygous tTAGFAP mice were bred
with heterozygous IGF-1pTRE mice [25]. Detailed characterization
of IGF-1 overexpressing mice was published previously [25].
Briefly, tTAGFAP mice carry the tTAGFAP transgene, obtained by
linking the GFAP promoter to tetracycline-controlled transacti-
vator protein (tTA) cDNA (Figure S1). The IGF-1pTRE transgene
was generated using cDNA coding for rat somatostatin signal
peptide/human IGF-1 fusion protein that is inserted into a pTRE
plasmid. By crossing tTAGFAP mice with IGF-1pTRE, double
transgenic mice carrying both the transgenes (tTAGFAP/IGF-
1pTRE ) were generated. In these double transgenic mice tTA is
expressed selectively in astrocytes where binding to TRE drives
IGF-1 expression. When doxycycline is provided, it binds to tTA
preventing tTA-TRE binding, and hence hIGF-1 expression
(Figure S1). From here on, the term IGF-1 transgenic (IGF-1Tg) is
used to describe the double transgenic mice in which astrocyte-
specific overexpression of IGF-1 can be suppressed by doxycy-
cline. Wild-type (WT) littermates were utilized as controls in all
studies.
Mice were fed with doxycycline supplemented mouse chow
(200 mg/kg) for the first 4 weeks of postnatal development to block
hIGF-1 transcription. Subsequently they received standard mouse
chow for at least four weeks to allow transgene expression prior to
surgery/injury. hIGF-1 mRNA was previously shown to be
induced in the hippocampus after 3–4 weeks of doxycycline
withdrawal [25]. A subset of mice in the doxycycline control study
remained on the doxycycline diet from birth until euthanasia.
Mice were housed at a maximum of 5/cage in a University of
Kentucky Medical Center animal vivarium at a constant
temperature (2362uC) with a 14/10-h light/dark cycle and
provided food and water ad libitum. All procedures involving
animals were approved by the University of Kentucky’s Institu-
tional Animal Care and Use Committee (approval # 2007–0191).
Controlled Cortical Impact Injury
The CCI injury was performed as previously described [9,17].
Anaesthesia was induced using 3% isoflurane. After securing the
head of the animal in a stereotaxic frame (David Kopf
Instruments, CA), anaesthesia was maintained using 2.5%
isoflurane delivered through a nose cone. A midline scalp incision
was made and a 5-mm diameter craniotomy was performed over
the left parietal cortex, lateral to the sagittal suture (1.5 mm lateral)
midway between Bregma and lambda (approximately 21.9 mm
Bregma). Sham-injured mice received a craniotomy under
isoflurane anesthesia. For CCI injury, a cortical contusion was
produced using a pneumatically driven impactor device (Precision
System Instruments, KY) with a 3 mm diameter rounded
impactor tip. The impact depth was set at either 0.5 mm or
1.0 mm, with a velocity of 3.5 m/s to produce moderate or severe
brain injury, respectively, as previously demonstrated using
histological and behavioral endpoints [9,26,27]. Histological
changes observed after 0.5 mm or 1.0 mm CCI were consistent
with our previous observations [9]. Animals were randomly
assigned to receive either sham injury (n=4–6/genotype for
histology, immunohistochemistry, western blotting and ELISA;
n=8/genotype for behavioral studies), or CCI brain injury (n = 8/
genotype for each time point for histology, immunohistochemistry;
n=5–8/genotype for each time point for western blotting and
ELISA; n=13/genotype for behavioral studies). After CCI or
sham injury, a circular disk made from dental cement was glued
over the craniotomy to protect the brain surface, and the scalp was
sutured. Mice were placed on a Hova-Bator Incubator (model
1583, Randall Burkey Co., TX) to maintain body temperature
until they regained consciousness, after which they were returned
to their home cages.
Tissue Preparation for Immunohistochemistry and
Histology
Animals were deeply anesthetised by sodium pentobarbital at
72 h after 0.5 mm CCI or 24 h, 72 h or 10d after 1.0 mm CCI
and transcardially perfused with heparinised saline followed by
10% buffered formalin. Brains were removed 24 h after post-
fixation in 10% formalin, cryoprotected using 30% sucrose
solution, and snap frozen in cold isopentane (#225uC). Frozen
brains were cut in a coronal plane at 40 mm thickness.
Immunohistochemistry
Immunohistochemistry was performed using published proto-
cols for frozen sections [17]. For IGF-1 labeling, antigen retrieval
was performed using 10 mM citric acid pH 6.0 at 60uC. Primary
antibodies used were anti-IGF-1 (rabbit polyclonal,1:1000,
National hormone and peptide program, CA) anti-GFAP (mouse
monoclonal,1:1000, Sigma, MA) and anti-NeuN (1:1000, Milli-
pore, MA). Secondary antibodies were conjugated with biotin
(Jackson Immunoresearch, PA) and, for amplification of the signal,
avidin-biotin-enzyme complex (Vector Laboratories, CA) was
used. For co-localization, sections were incubated with anti-IGF-1
(1:500), anti SOX-2 (rabbit polyclonal, 1:500, Millipore) or anti-p-
Akt (rabbit monoclonal, 1:300, Cell Signalling Technology, MA)
in combination with either anti-NeuN (1:500, Millipore) to label
neurons or anti-GFAP (1:300) to label astrocytes. Secondary
antibodies were conjugated with Alexa-488, Cy-3 or Alexa-594
(Invitrogen, CA). Omission of primary antibody served as a
negative control. Slides were observed and imaged using an
epifluorescence microscope (AX 80 Olympus, PA), a spinning
confocal microscope (IX-81, Olympus) equipped with a CCD
camera or a Nikon Eclipse Ti-C2 confocal microscope. Confocal
images were acquired as Z-stacks (0.5 mm thickness) and the
representative image is a maximum intensity projection image
from the Z-stack. Images obtained from the spinning confocal
microscope were modified using the Image Pro flatten filter to
reduce the intensity variations in the background pixels.
Tissue Preparation for ELISA and Western Blotting
At 24 or 72 h after brain injury, mice were euthanized by CO2
asphyxiation and brains were rapidly removed onto an ice cold
dissection plate. Contralateral and ipsilateral hippocampi were
IGF-1 Mediated Neuroprotection after TBI
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dissected and homogenized separately in chilled lysis buffer
(1%Triton, 20 mM Tris–HCl, 150 mM NaCl, 5 mM EGTA,
10 mM EDTA, 10% glycerol, protease inhibitors) and centrifuged
at 10,000 g for 30 min at 4uC. The supernatants were collected for
ELISA and western blotting. Protein concentrations were deter-
mined using a BCA protein assay kit (Pierce Biotechnology, IL).
Quantification of hIGF-1 by ELISA
IGF-1 ELISA was performed using QuantikineH human IGF-1
ELISA kit (R&D Systems Inc., MN) according to manufacturer’s
directions. Briefly, hippocampal samples were pretreated to
dissociate IGF-1 from IGF binding proteins (BPs). Pretreated
samples and hIGF-1 standards (0.094–6.0 ng/ml) were then
pipetted in duplicate onto a microwell plate coated with a
monoclonal antibody specific to hIGF-1. After 2 h incubation the
unbound antigens were removed by rinsing. HRP enzyme-linked
polyclonal antibody specific to hIGF-1 was then added to the wells
and incubated for 1 h. The wells were rinsed and substrate
solution was added for 30 min. Development was stopped by
adding 1N hydrochloric acid. Optical density (OD) was recorded
using a microplate reader (Tecan, NC) at 450 nm with a reference
filter of 540 nm. Readings at 540 nm were subtracted from OD at
450 nm to correct for background.
Western Blot
The western blot analyses were performed as previously
described [17]. Electrophoresis was performed using 10–30 mg of
protein extracts on a 3–8% Tris-acetate gel at 150V and
transferred onto nitrocellulose membranes. The membranes were
blocked for 1 h in 5% dry milk and then incubated overnight with
primary antibody, followed by 1 h incubation in secondary
antibody. The antibodies used were anti-p-Akt ser 473 (rabbit
monoclonal, 1:2000, Cell Signaling Technology), anti-Akt (rabbit
monoclonal, 1:2000, Cell Signaling Technology), anti-GFAP
(1:5000) and anti–b-actin (mouse monoclonal, 1:5000, Calbio-
chem Inc, CA). Secondary antibodies were conjugated to an
infrared dye (1:8000 IRDye800CW, Rockland, PA). After
washing, the membranes were imaged and quantified using a Li-
Cor Odyssey Infrared Imaging System (Li-Cor, NE). Following p-
Aktser and GFAP development, the blots were reprobed for actin.
All samples were run in duplicate. For quantification, the OD of
each band was divided by its respective actin OD and then
normalized to the mean relative OD for WT sham mice to allow
comparison across gels.
Fluoro-jade C Staining and Quantification of
Hippocampal Neuronal Death
For each brain, every tenth section (400 mm apart) spanning the
region of the cerebrum that contains hippocampus (Bregma levels
21.0 mm to 23.5 mm) was mounted and air dried onto gelatin-
coated slides. Fluoro-jade C staining for degenerating neurons [28]
has been used to quantify trauma-induced hippocampal neuron
death [29,30]. Staining was performed according to manufactur-
er’s directions. Briefly, slides were treated with 1% NaOH for
5 min followed by 2 min each in 80% ethanol, 70% ethanol, and
distilled water. Slides were then placed in a 0.06% potassium
permanganate solution for 10 min and rinsed in distilled water,
before staining for 10 min with 0.0001% Fluoro-jade C (Millipore)
in 0.1% acetic acid. Slides were then rinsed in distilled water, dried
on a slide warmer, immersed in Xylenes, and coverslipped in
Cytoseal XYL (Richard-Allan Scientific, MI). All slides were
stained in the same experimental batch. For quantification, the
entire dentate gyrus (DG) and CA-3 areas of the hippocampus
from each section were imaged at 20X magnification using an epi-
fluorescence microscope equipped with a FITC filter (AX80,
Olympus). Exposure time and sensitivity were kept constant in all
the photos. Multiple images were overlaid to create a high
resolution montage of the entire DG or CA-3 (Adobe illustrator-
CS4, Adobe systems Inc, CA). Using Image Pro Plus (Media
Cybernetics, Inc, MD) software, an area of interest was selected by
tracing around the granule cell layer of DG or the CA-3 pyramidal
neuronal layer including CA-3c. A minimum intensity threshold
was set using the background intensity of the staining and was kept
constant for sections from the same brain. Size exclusion criteria
were set at 3 mm2 to exclude fluorescent neuronal debris and 800
mm2 to exclude large non-neuronal dye accumulations if any. The
number of Fluoro-jade C labeled cells for each region was
averaged across all sections for a given animal.
Nissl Staining
Every tenth section spanning the entire cerebrum was mounted
and air dried onto gelatin-coated slides. The slides were
rehydrated through graded ethanol solutions, immersed in water,
stained with 0.5% Cresyl Violet (Acros Organics, NJ), dehydrated
through graded ethanol solutions, cleared with Xylenes (Fisher
Scientific, NJ), and mounted using Permount (Fisher Scientific).
Motor Behavior Assessment
A modified neurological severity score (NSS), adapted from
Tsenter and colleagues [31] was used as described by us previously
[26] with minor modifications in the scoring paradigm to assess
motor deficits and recovery of motor function at 1, 2, 3 and 4 days
post-injury. At 24 h before brain injury, mice were acclimated to
each of four elevated, 60 cm long Plexiglas beams of different
widths (3.0, 2.0, 1.0 and 0.5 cm) and a 0.5 cm diameter wooden
rod. After injury, each mouse received a maximum score of four if
it successfully crossed the beam with normal forelimb and
hindlimb usage and position. Three points were given for
successfully crossing the beam despite either a forelimb or
hindlimb hanging from the beam. Two points were given for
crossing the beam with both a forelimb and hindlimb hanging
from the beam. One point was given for crossing the beam despite
inverting underneath the beam one or more times. If a mouse
became inverted on the beam, it was righted and allowed to
continue across. For the rod, each mouse received two points for
successfully crossing the rod and one point was given for crossing
despite inverting more than three times. A mouse received a score
of zero if it did not move along or fell off of the beams or rod. NNS
is given as a total score (maximum 18) obtained per mouse.
Cognitive Performance Evaluation
Memory function was evaluated using a novel object recogni-
tion (NOR) paradigm [27,31]. At 24 h prior to injury, mice were
individually acclimatized for one hour to a clear plastic cage
(32620614 cm) with an open top prior to the introduction for
5 min of two identical LegoH DuploH minifigures placed in
opposite corners of the cage. On day 7 after CCI, each mouse was
re-introduced to its respective testing cage and allowed to explore
freely for one hour. The two original objects were re-introduced to
the cage and the time spent exploring each object was recorded
over a 5 min period. After a 4 h delay, the mice were returned to
their test cages where one of the original objects was replaced with
a novel object. Time spent exploring each object was recorded for
5 min. A recognition index was calculated as the time spent
exploring the novel object as a percent of total object exploration
time.
IGF-1 Mediated Neuroprotection after TBI
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Stereological Counting of CA-3 Neurons
To estimate the total number of NeuN positive cells in
hippocampal CA-3 region, unbiased stereological cell counting
using the optical fractionator technique [32,33] was performed at
10d post-injury on a cohort of mice randomly selected from those
that received behavioral evaluations. For each brain, every 5th
section (i.e. 200 mm intervals) from bregma levels 21.0 mm to
22.2 mm encompassing the dorsal hippocampus was NeuN
immunostained. Counting was restricted to the dorsal hippocam-
pus because CCI results in CA-3 loss predominantly in the dorsal
hippocampus, and because changes in organization and neuronal
packing density in the ventral hippocampus would require a
different set of sampling parameters. Neurons in CA-3 area were
visualized using a 60X oil immersion objective on an Olympus
BX-51 microscope equipped with a motorized stage and
stereology software (Bioquant Life Science, V8.40.20; Bioquant
Image Analysis, Nashville, TN). Regions of interest were traced
and overlaid with a counting grid (1506150 mm2 ) for the optical
disector method. Neurons were counted within the set disector
area (20620 mm2). The total number of CA-3 neurons was
estimated using the formula, S= total cells counted61/ssf61/
asf61/tsf, where ‘ssf’ is the section sampling fraction, ‘asf’ is area
sampling fraction and ‘tsf’ is thickness sampling fraction.
Dentate Hilus Neuronal Counts
Four sections per brain selected at 400 mm intervals spanning
from Bregma 21.5 mm to 22.7 mm were used for counting
NeuN positive neurons in the dentate hilus (DH) using Image Pro
Plus software. For each section, a photo montage was created for
the DH and size exclusion criteria applied as described in the
Fluoro-jade C quantification section. Total numbers of neurons in
four sections were calculated for each animal.
Statistical Analyses
All quantification procedures and behavioral analyses were
performed by an investigator blinded to the injury and genotype
conditions. Data are presented as mean+standard error of mean
(SEM). For hIGF-1 ELISA data, western blot quantification, and
NeuN neuronal counts statistical significance among experimental
groups was determined by one-way analysis of variance (ANOVA).
Where appropriate, ANOVA was followed by Newman-Keuls
post-hoc analyses. Fluoro-jade C cell counts were analyzed using t-
tests. NOR and modified NSS data were analyzed using a
Kruskal-Wallis ANOVA at a given time point, followed by Mann-
Whitney U tests. Statistical tests were performed using Statistica
(StatSoft Inc, OK) software. For all comparisons p,0.05 was
considered statistically significant.
Results
Astrocyte-specific Overexpression of IGF-1
To verify astrocytic expression of IGF-1 we performed IGF-1
immunostaining in sham and brain-injured IGF-1Tg and WT
mice, using an IGF-1 antibody that detects both mouse and
human-IGF-1. Consistent with developmental downregulation of
IGF-1 in the CNS, basal IGF-1 expression in the hippocampus of
WT and IGF-1Tg sham-injured mice was low, with only weak
immunoreactivity in cells with neuronal morphology (data not
shown). Brain injury did not produce a noticeable change in IGF-1
expression in WT mice (data not shown). In contrast, after CCI
brain injury, IGF-1 immunostaining was markedly increased in
IGF-1Tg mice throughout the hippocampus ipsilateral to the
impact in cells with an astrocytic morphology. Injury-induced
increases in IGF-1 immunoreactivity in IGF-1Tg mice were even
more prominent at 72 h (Figure 1A). Among the hippocampal
subregions, the DG and CA-3 are known to be most susceptible to
CCI brain injury [9]. In the DG, both the molecular layers and
hilar region exhibited robust IGF-1 immunoreactivity (Figure 1A),
while IGF-1 positive cells were absent from the DG granule cell
layers. In comparison, only a few scattered IGF-1 positive cells
with astrocytic morphology were observed in the contralateral
hippocampus of brain- injured IGF-1Tg mice (Figure 1A). Post-
traumatic induction of hIGF-1 expression was quantified using an
ELISA specific for hIGF-1. While levels of hIGF-1 were unde-
tectable in sham controls and in brain-injured WT mice (data not
shown), CCI in IGF-1Tg mice produced a progressive increase in
hIGF-1 levels from 24 to 72 h in the hippocampus ipsilateral to
the impact (Figure 1B). The contralateral hippocampus exhibited
smaller increases in hIGF-1 at 24 h and 72 h, reaching levels only
approximately one third of those in the ipsilateral hippocampus
(Figure 1B). In order to verify the cellular origin of IGF-1
expression in IGF-1Tg mice, dual immunofluorescence for IGF-1
and GFAP or NeuN was performed. Most GFAP-positive
astrocytes (approximately 85%) were co-labeled with IGF-1,
whereas NeuN-positive neurons did not co-express IGF-1,
confirming astrocytic localization (Figure 1C).
Astrocyte-selective IGF-1 Overexpression Promotes GFAP
Upregulation and Astrocytic Hypertrophy
Basal astrogliosis, visualized using immunoreactivity for GFAP,
appeared equivalent in WT sham and IGF-1Tg sham mice
(Figure 2A). Brain injury resulted in robust reactive astrocytosis,
indicated by increased GFAP staining, throughout the ipsilateral
hippocampus at 24 and 72 h post-injury. However, trauma-
induced astrogliosis was more pronounced in IGF-1Tg mice,
characterized by greater astrocyte hypertrophy (Figure 2A). In
addition, GFAP-positive cells within the subgranular layer or hilus
of IGF-1Tg mice extended long processes through the DG granule
layer, while WT mice typically exhibited little GFAP labeling
within the granule layer (Figure 2A). To explore the possibility that
these processes arose from radial glial stem cells, we performed
dual immunofluorescence staining with antibodies against GFAP
and SOX-2, a transcription factor commonly used as a stem cell
marker. Many of GFAP-positive processes were found to be
associated with SOX-2 positive nuclei (Figure 2B), raising the
possibility that IGF-1 overexpression may alter stem cell as well as
astrocyte GFAP expression. To confirm that this increased GFAP
expression was specific to the genetic overexpression of IGF-1, we
blocked IGF-1 overexpression by administering doxycycline
(200 mg/kg feed) to IGF-1Tg mice from birth until euthanasia
72 h after induction of moderate brain injury. Doxycycline
administration effectively prevented IGF-1 overexpression in the
hippocampus as shown by a lack of IGF-1 immunostaining (Figure
S2). In the absence of IGF-1 overexpression, injury-induced
astrocytosis throughout hippocampus in transgenic mice was
comparable to that observed in WT mice (Figure S2). These data
strongly support that astrocyte-derived IGF-1 enhances injury-
induced hippocampal astrocytosis and hypertrophy.
IGF-1 Overexpression Increases GFAP Protein Levels
In order to quantify the effect of conditional astrocyte-specific
IGF-1 overexpression on GFAP protein levels, we performed
western blotting of the hippocampus after both moderate and
severe brain injury. Consistent with immunohistochemical staining
for GFAP (Figure 2A), WT and IGF-1Tg sham control mice had
comparable GFAP levels (Figure 3). Brain-injured WT mice
showed delayed upregulation of GFAP with significantly increased
levels at 72 h, but not 24 h. At 72 h, moderate injury to WT mice
IGF-1 Mediated Neuroprotection after TBI
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resulted in a 2.5 fold increase in GFAP levels while severe injury
produced a 3-fold increase (Figure 3D, 3E). IGF-1Tg mice
exhibited an earlier increase in GFAP, but this increase at 24 h
was statistically significant only after severe injury (Figure 3C). By
72 h post-injury, GFAP levels in the brain-injured IGF-1Tg mice
were elevated approximately 4-fold above IGF-1Tg sham mice,
and were significantly elevated above levels in WT brain-injured
mice at both severities (Figure 3D, 3E).
IGF-1 Overexpression Enhances Akt Phosphorylation
In order to investigate the downstream signaling pathways of
IGF-1, western blot analysis for p-Akt ser was performed.
Hippocampal samples harvested at 24 or 72 h from WT and
IGF-1Tg sham mice showed no statistically significant differences,
although p-Akt ser levels appeared slightly elevated in IGF-1Tg
sham mice at 72 h (Figure 4). Although brain injury appeared to
result in a delayed decrease in p-Akt ser in WT mice by 72 h, levels
were not significantly different from sham (Figure 4D, 4E). At 24 h
following either moderate or severe CCI, IGF-1 overexpression
significantly increased phosphorylation of Akt over levels in IGF-
1Tg shams and brain-injured WT mice (Figure 4B, 4C). p-Akt
levels were effectively maintained at baseline (sham) levels at 72 h
in IGF-1Tg mice, countering the apparent decline in p-Akt ser in
WT mice (Figure 4D, 4E). Indeed, in the severely injured IGF-1Tg
group at 72 h, Akt phosphorylation was elevated compared to
injured WT mice (Figure 4E). To identify the phenotype of cells
expressing p-Akt, we labeled brain sections with p-Akt and either
NeuN or GFAP. In the hippocampus of IGF-1Tg mice
Figure 1. Trauma-induced astrocyte-specific IGF-1 overexpression. A) Coronal sections from IGF-1Tg mice show a marked increase in IGF-1
immunolabeling in the hippocampal dentate gyrus (DG) and CA-3 regions in the ipsilateral (ipsi) hemisphere compared to the contralateral (contra)
after lateral controlled cortical impact (CCI) brain injury. Immunohistochemical staining was performed using an antibody that detects both human
and mouse IGF-1. Representative picture is taken from an IGF-1Tg mouse 72 h after CCI. Scale bar = 100 mm. B) Quantification of IGF-1 expression
using a human-specific IGF-1 ELISA. IGF-1 concentrations increased progressively in the ipsilateral hippocampus of IGF-1Tg mice at 24 h and 72 h
after severe CCI brain injury. Data plotted as mean+SEM. * p,0.05 comparing injured with sham, ! p,0.05 comparing ipsilateral to contralateral, and
# p,0.05 comparing 72 h to 24 h. C) Confocal images taken from ipsilateral hemisphere bordering the contused cortex demonstrate widespread
colocalization of IGF-1 (green) with the astrocyte-specific marker GFAP (red) in brain-injured IGF-1Tg mice. No co-localization of IGF-1 (green) and
neuron-specific NeuN (red) was observed. Scale bar = 50 mm for C.
doi:10.1371/journal.pone.0067204.g001
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Figure 2. Enhanced astrocytosis in IGF-1Tg mice after brain injury. A) Immunoreactivity for GFAP was similar in the hippocampus of WT and
IGF-1Tg sham mice. Controlled cortical impact (CCI) brain injury induced astrocytosis in the ipsilateral hippocampus which was more profound in IGF-
1Tg mice than in WT mice (shown for 72 h, moderate severity). Boxed areas in the molecular layer of the DG and the apex of the dentate hilus (DH)
are magnified in the two lower panels to illustrate hypertrophied astrocytes (arrows) and elongated astroglial processes (arrowheads). B)
Representative confocal images from the DH of an IGF-1Tg mouse showing GFAP-stained processes arising from SOX-2 positive cells (arrows). DH:
dentate hilus, GL: granule layer. Scale bars = 200 mm for low magnification images and 50 mm (A) or 100 mm (B) for high magnification images.
doi:10.1371/journal.pone.0067204.g002
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immunolabeling for p-Akt was localized to neurons (NeuN) and a
subset of astrocytes (GFAP) (Figure S3).
Quantification of total Akt protein levels by western blotting
revealed no differences among sham or brain-injured hippocampal
samples from WT and IGF-1Tg, at 24 or 72 h after moderate or
severe CCI (Figure S4), confirming that changes in pAkt protein
levels were indicative of changes in Akt activation.
Selective Overexpression of IGF-1 in Astrocytes Promotes
Hippocampal Neuronal Survival
CCI brain injury results in acute hippocampal neurodegener-
ation that can be detected using Fluoro-jade C. After either
moderate or severe brain injury, Fluoro-jade C positive neurons
were located predominantly in the hippocampal DG and CA-3
areas. Within the DG, many Fluoro-jade C positive neurons were
located in the inner granular layer and subgranular zone
(Figure 5A). Following severe CCI, numbers of Fluoro-jade C
positive neurons in the ipsilateral hippocampal DG were
significantly lower in IGF-1 overexpressing mice at both 24 h
and 72 h (Figure 5B, 5D). However, in the CA-3 region, numbers
of degenerating neurons were only modestly decreased in IGF-
1Tg mice at 24 h (Figure 5D). At 72 h following moderate CCI,
IGF-1 overexpression resulted in robust protection against
neuronal death in both the CA-3 and DG (Figure 5C). No
Fluoro-jade C stained neurons were observed in the hippocampus
of sham-injured mice regardless of genotype.
Because hippocampal neurodegeneration assessed using Fluoro-
jade C staining captures neuronal degeneration ongoing at the
time of euthanasia, Nissl staining was also used to evaluate
cumulative neuron survival over the post-traumatic period. Severe
(1.0 mm) brain injury in WT mice resulted in few Nissl-stained
hilar cells with normal neuronal morphology, loss of Nissl staining
in the CA-3 pyramidal layer, and thinning of the CA-1 pyramidal
layer and DG granule layers at 72 h post-injury (Figure 6).
Qualitative analyses indicated that IGF-1 overexpression provided
protection against cell loss in CA-1, CA-3 and DG hippocampal
areas (Figure 6). Following moderate (0.5 mm) CCI, surviving
hilar neurons were more abundant in IGF-1 overexpressing mice
than in WT mice (Figure S5), consistent with a neuroprotective
effect IGF-1.
To determine if IGF-1 hippocampal protection was sustained
and to provide quantitative assessment of neuron survival, a
separate cohort of IGF-1 Tg and WT mice received severe CCI
and cell counting was performed at 10d post-injury in the CA-3
pyramidal layer and the dentate hilus (Figure 7). Numbers of
NeuN-positive neurons were significantly decreased in brain-
injured WT mice in the CA-3 (60% neuron loss, Figure 7B) and
dentate hilus (30%, Figure 7C). IGF-1 overexpression increased
the number of surviving neurons in both the CA-3 (Figure 7B) and
dentate hilus (Figure 7C) subregions of hippocampus at 10d post-
injury. In sham-injured mice, numbers of neurons in both the CA-
3 and dentate hilus were equivalent in WT and IGF-1Tg mice.
IGF-1 Overexpression Improves Post-traumatic
Behavioral Dysfunction
To determine if the neuroprotection provided by IGF-1
overexpression was associated with behavioral improvement,
motor function was evaluated by modified NSS and hippocam-
pal-mediated cognitive performance by a NOR task at 7d post-
injury. Brain injury resulted in significant coordinated motor
function deficits as indicated by low NSS scores over the first four
days after CCI in both WT and IGF-1Tg mice compared to their
respective sham group (Figure 8A). However, injured IGF-1Tg
mice achieved significantly higher NSS scores compared to injured
WT mice at every time point assessed (Figure 8A), indicating that
IGF-1 overexpression attenuated posttraumatic motor dysfunc-
tion. Motor performance of WT and IGF-1Tg sham mice was
equivalent. Injury induced a significant impairment in memory in
WT mice as revealed by a recognition index of 50%, indicative of
no preference for a novel object over a familiar object (Figure 8B).
Brain-injured IGF-1Tg mice did not exhibit a cognitive deficit
relative to IGF-1Tg sham mice. Furthermore, brain- injured IGF-
1Tg mice showed greater exploration of the novel object
compared to brain-injured WT mice (Figure 8B), suggesting that
IGF-1 overexpression improved memory of the familiar object.
Discussion
In animal models of TBI, systemic IGF-1 administration
improves behavioral outcomes [22,23]. However, the mechanisms
underlying IGF-1 mediated recovery of neurological function are
not known. One of the many effects of IGF-1 in the CNS is
promoting neuronal survival through activation of the PI3K/Akt
pathway. Hence, we sought to investigate the neuroprotective
Figure 3. IGF-1 overexpression increased hippocampal GFAP
levels following brain trauma. A) Representative western blot
images for ipsilateral hippocampal samples probed with anti-GFAP and
anti-actin antibodies. Blots illustrate expression at 72 h after severe
controlled cortical impact (CCI) brain injury or sham injury (Sh). Relative
expression of hippocampal GFAP at 24 h (B,C) and 72 h (D,E) following
either 0.5 mm (B,D) or 1.0 mm (C,E) depth CCI in wildtype (WT, open
bars) and IGF-1 transgenic (IGF-1Tg, closed bars) mice. Optical density
from each band was normalised to its respective actin band and then
group means were normalised to the mean of the WT sham group. Data
represented as mean+SEM. * p,0.05 and # p,0.05 comparing CCI
with sham, and ! p,0.05 comparing IGF-1Tg to WT.
doi:10.1371/journal.pone.0067204.g003
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potential of IGF-1 following brain injury focusing on the
hippocampus, a structure vulnerable to trauma and critical for
many aspects of learning and memory. Employing a targeted
delivery technique that exploits reactive astrocytosis to deliver
regionally specific IGF-1 in a delayed fashion after TBI, we
demonstrate for the first time that IGF-1 provides hippocampal
neuroprotection in addition to improving cognitive and motor
function following brain injury. Our data also points to the
activation of the pro-survival protein Akt as a potential mechanism
underlying the neuroprotective effects of IGF-1.
Reactive astrocytosis typically occurs in a delayed fashion within
and around areas of neuronal damage, with enhanced GFAP
expression and glial scar formation progressing over several days
[9,34,35]. Our western blot data demonstrates that in WT mice
increases in hippocampal GFAP levels are delayed more than 24 h
after CCI, although immunohistochemistry revealed reactive
astrocytes by 24 h, consistent with previous studies [9,35]. Linking
hIGF-1 overexpression to GFAP expression was effective in
producing a progressive increase in IGF-1 over 72 h that was
three-fold higher in the ipsilateral compared to contralateral
hippocampus, demonstrating that IGF-1 was targeted to areas of
neuronal damage and death. Similar approaches using genetically
modified astrocytes overexpressing BDNF or Nrf2 have proven
beneficial in models of neurodegenerative diseases where astro-
Figure 4. Akt phosphorylation is augmented in IGF-1Tg mice. A) Representative western blot images for ipsilateral hippocampal samples
probed with anti-p-Akt and anti-actin antibodies. Blots illustrate expression at 72 h after severe (1.0 mm) controlled cortical impact (CCI) brain injury
or sham injury (Sh). Relative expression of hippocampal p-Akt at 24 h (B,C) and 72 h (D,E) following either 0.5 mm (B,D) or 1.0 mm (C,E) CCI in
wildtype (WT, open bars) and IGF-1 transgenic (IGF-1Tg, closed bars) mice. Optical density from each band was normalised to its respective actin
band and then group means were normalised to the mean of WT sham group. Data are represented as mean+SEM. # p,0.05 comparing CCI with
sham, and ! p,0.05 comparing IGF-1Tg to WT.
doi:10.1371/journal.pone.0067204.g004
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cytosis is a hallmark of disease progression [36–38]. Measurements
of IGF-1 at additional time points will be required to more fully
elucidate the onset and duration of IGF-1 overexpression in brain-
injured IGF-1Tg mice. However, based on the return of
hippocampal GFAP mRNA levels to near baseline by 2 weeks
after CCI brain injury [35], IGF-1 levels may also return to
baseline by that time.
We previously showed that brain injury triggers a transient
increase in cortical IGF-1 at 1 h followed by activation of p-Akt at
6 h that was not sustained [17]. In the present study, p-Aktser levels
were unchanged at 24 h and decreased slightly at 72 h in WT
mice. Together our data are consistent with a previous study of
severely brain-injured rats where p-Aktser levels were increased at
2–6 h and reduced at 24–72 h in the hippocampus [39].
Overexpression of IGF-1 enhanced p-Aktser levels selectively in
brain-injured mice. Sham-injured IGF-1Tg mice, in contrast, had
p-Akt levels comparable to WT mice, confirming that Dox-
mediated suppression of IGF-1 overexpression during first four
weeks of postnatal development was sufficient to prevent basal
increases in p-Akt levels reported with constitutive IGF-1
overexpression [40]. Posttraumatic IGF-1-mediated increases in
p-Aktser were not due to an increase in Akt synthesis, as total Akt
protein levels did not change. Although IGF-1 and GFAP levels
increased progressively after CCI brain injury in IGF-1Tg mice,
increases in p-Akt in brain-injured IGF-1 Tg mice were either
comparable or smaller at 72 h compared to 24 h. This could be
due, in part, to IGF-1 overexpression having to compensate for
injury-induced decreases in p-Akt levels by 72 h. Furthermore, it is
likely that turnover of activated Akt occurs much faster than that
of GFAP, a structural protein; protein levels at 72 h may therefore
represent cumulative increases to a greater extent for GFAP than
for pAkt. Diminishing levels of Akt activation over time may also
reflect decreased bioavailability of IGF-1 due to upregulation of
IGF-binding proteins in response to prolonged IGF-1 overexpres-
sion.
In brain-injured mice, Akt was activated in neurons and
astrocytes. Neurons are more susceptible to cell death when p-Akt
levels are low, while neurons with enhanced Akt phosphorylation
appear to be protected after CNS insults [41,42]. PI3K/Akt
signaling is the primary survival pathway initiated by IGF-1 in
neurons and oligodendrocytes, leading to the inhibition of pro-
apoptotic factors such as Bad, caspase-3, caspase-9, Forkhead
transcription factors and NF-kB [43,44]. While Akt activation may
have contributed to the neuroprotective effect observed in injured
IGF-1Tg mice, additional studies are necessary to establish a
causal role for p-Akt or other downstream signaling molecules
such as MAP-kinase [45]. Akt activation is also a key event in
synaptic plasticity and the persistence of long-term potentiation
[46,47]. This may have relevance when considering the improved
cognitive performance of IGF-1Tg mice.
The role of IGF-1 in preventing apoptotic death and promoting
cell survival has been well established in in vitro studies [14,15,48–
50]. Although IGF-1 appears neuroprotective in models of stroke
and ischemic injury [51–54], this is the first study to assess
neuroprotective actions of IGF-1 in a clinically relevant model of
brain trauma. As previously reported for the CCI model
[26,55,56], Fluoro-jade C positive dying neurons were mainly
present in hippocampal subregions CA-3 and DG granule layers.
IGF-1 overexpression provided notable protection against acute
neurodegeneration in both areas after moderate severity injury.
After severe contusion injury, IGF-1 significantly reduced acute
DG neuron death at 24 and 72 h post-injury while it appeared to
lessen CA-3 neurodegeneration only at 24 h. However, counts of
surviving neurons at 10d post-injury confirmed that IGF-1
overexpression was neuroprotective in both the CA-3 and DG
regions after severe contusion injury. The discrepancy between
IGF-1 effects on acute CA-3 neurodegeneration and longer term
Figure 5. IGF-1 overexpression attenuated hippocampal neurodegeneration after trauma. A) Fewer Fluoro-jade C positive neurons were
observed in the dentate gyrus (DG) of IGF-1 transgenic (IGF-1Tg) mice compared to wildtype (WT) mice at 72 h after cortical impact. Representative
pictures are from severely (1.0 mm) injured WT and IGF-1Tg mice. Scale bar = 100 mm. Fluoro-jade C positive neuronal counts from ipsilateral
hippocampal subregions CA-3 and DG after 0.5 mm (C) or 1.0 mm (B, D) cortical impact. Data are represented as mean+SEM. * p,0.05 comparing
IGF-1Tg and WT.
doi:10.1371/journal.pone.0067204.g005
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Figure 6. IGF-1 overexpression promoted hippocampal neuronal survival at 72 h after severe brain injury. Representative images of
the ipsilateral hippocampus (HP) from Nissl-stained brain sections illustrate pallor or thinning of CA-3 and CA-1 areas of pyramidal layer (arrows) in
wildtype (WT) mice. Higher magnification images from DG, CA-3 and CA-1 areas demonstrate hilar and CA-3 neuronal loss and thinning of the CA-1
pyramidal layer. IGF-1 overexpressing (IGF-1Tg) mice showed marked neuroprotection in each hippocampal subregion. Arrowheads point to hilar
neurons. Scale bars = 500 mm (top HP panel), 100 mm for DG panel, 50 mm for CA-3 and CA-1 panels.
doi:10.1371/journal.pone.0067204.g006
Figure 7. IGF-1 overexpression provided hippocampal neuroprotection 10d after severe brain injury. A) Representative images of the
ipsilateral hippocampus from NeuN-immunostained brain sections after severe (1.0 mm) brain injury showing CA-3 neuronal loss (arrow). Scale
bar = 200 mm. B) Stereological estimate of total number of CA-3 pyramidal neurons within the dorsal hippocampus (21.0 to 22.2 mm Bregma) and
C) Dentate hilar neuronal counts (total number of cells in 4 sections/animal) from wildtype (WT, open bars) and IGF-1 transgenic (IGF-1Tg, closed
bars) mice. IGF-1 overexpression significantly increased neuronal survival in both regions. Data are expressed as mean+SEM. * p,0.05 and # p,0.05
comparing CCI with sham, and ! p,0.05 comparing IGF-1Tg to WT.
doi:10.1371/journal.pone.0067204.g007
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CA-3 neuron survival may reflect limitations in quantifying cell
death utilizing Fluoro-jade C, which provides a ‘snapshot’ of dying
cells and may not convey sufficient information about alterations
in the time course of neurodegeneration. It is also possible that
IGF-1 exerts region-specific effects. Following ex vivo hippocam-
pal stretch insult, DG neurons show higher caspase-3 activation
compared to CA-3 neurons, in which calpain activity dominated
[57]. Because of its potent anti-apoptotic effects [48,58,59], IGF-1
could be more effective in rescuing DG neurons. Enhanced DG
neuron survival may have important implications in light of
published observations that Fluoro-jade C positive DG neurons
are predominantly doublecortin-expressing immature neurons
[56] and newborn neurons are thought to mediate cognitive
recovery after TBI [60].
Higher GFAP levels and enhanced astrocytic hypertrophy were
observed in brain-injured IGF-1Tg mice compared to WT mice
suggesting that astrocyte-derived IGF-1 exerted autocrine as well
as paracrine effects. Increased GFAP levels could reflect GFAP
upregulation or increased glial proliferation. IGF-1 is a potent
mitogen for neural cells, particularly astrocytes [20,61] and
oligodendrocytes [62,63]. Although we did not examine the full
time course of posttraumatic astrocytosis, it seems likely that
reactive astrocytosis would be prolonged in IGF-1Tg mice
compared to WT given the increased GFAP levels within the
first 72 h in IGF-1Tg mice. The autocrine actions of astrocyte-
derived IGF-1 might then contribute to a feed-forward loop in
which increased GFAP expression drives continued increases in
IGF-1 levels, prolonging not only reactive astrocytosis but also
IGF-1 expression. Reactive astrocytosis has long been considered
detrimental due to its roles in inhibiting axonal regeneration and
releasing inflammatory cytokines [64,65]. However, astrocytosis
may also be beneficial after injury by forming a physical and
biochemical barrier to separate a contused area from healthy
tissue, limiting the spread of inflammatory molecules and cells
[66,67]. Indeed, removal of reactive astrocytes after TBI has been
shown to worsen tissue loss and behavioral performance [68].
Astrocytosis involves an early hypertrophic response and a
subsequent hyperplastic response [69]. It is interesting to note
that the acute hypertrophy stage is considered responsible for the
beneficial effects of astrocytosis [70] and that IGF-1 overexpres-
sion produced a more pronounced hypertrophic response.
In addition, astrocytes with long processes that resemble radial
glia were observed in the DG of brain-injured IGF-1Tg mice.
GFAP-positive astrocytes with a radial glia-like morphology that
reside in SGZ are considered as stem cells [71]. Because radial
glial stem cells also express SOX-2, we performed dual labeling of
GFAP and SOX-2. GFAP positive astrocytes were associated with
SOX-2 positive nuclei raising the possibility that they are stem
cells residing in the SGZ. Effects of IGF-1 on radial glia-like cells
in the hippocampal SGZ could point to a role for IGF-1 in brain
remodeling following trauma. Effects of IGF-1 on post-traumatic
neurogenesis are currently under investigation in our laboratory.
Thus additional studies are warranted to determine if enhanced
neuronal survival and improved behavioral function after TBI in
IGF-1 overexpressing mice is due to direct effects of IGF-1 on
neurons or indirect effects mediated through astrocytes.
Cognitive and motor improvements have been observed in
brain-injured rodents receiving systemically administered IGF-1
[22,23]. Although exogenous IGF-1 administration improves
behavioral outcome in brain-injured rodents, previous studies
did not examine a link between functional improvements and
cellular neuroprotection. Furthermore, systemic delivery of IGF-
1 can be associated with undesirable side effects such as weight
gain, hypoglycemia and tumorigenesis due to IGF-1’s effects on
multiple organ systems [23,24,72]. Our targeted IGF-1 delivery
technique demonstrates the direct CNS effects of IGF-1 on
behavioral function. Improved novel object recognition in IGF-
1Tg mice may be related to enhanced hippocampal neuronal
survival, as hippocampal neuronal loss has been shown to correlate
with cognitive deficits in brain-injured rodents [73,74]. However,
IGF-1 overexpression also attenuated motor dysfunction, consis-
tent with previous observations of motor improvement following
systemic IGF-1 administration in rats [23]. These findings raise the
possibility that IGF-1 overexpression may be mediating effects in
multiple brain regions. CCI brain injury is known to induce
extensive astrocytosis not only in the hippocampus, but also in the
cortex. If astrocyte-derived IGF-1 is neuroprotective in the cortex,
this could contribute to improved motor function in IGF-1Tg mice
after brain injury, as early impairment in motor function after TBI
has been correlated with the volume of cortical injury [31]. The
effects of IGF-1 overexpression on injury-related neuropathology
in the cortex are currently under investigation.
In conclusion, enhancing IGF-1 expression by astrocytes
provided hippocampal neuroprotection and improved memory
and motor function after TBI. These data provide compelling
Figure 8. IGF-1 expression reduced post-traumatic behavioral
impairment after severe brain injury. A) In the modified
neurological severity score (NSS), a test series of beam walking tasks,
IGF-1 overexpressing (IGF-1Tg) mice exhibited significantly better
coordinated motor function compared to wildtype (WT) mice over
the first 4d after severe (1.0 mm) CCI. B) In the novel object recognition
(NOR) does task, the recognition index represent the percent
exploration time spent on the novel object. IGF-1 overexpression
prevented posttraumatic memory impairment at 7d post-injury. Data
expressed as mean+SEM. * p,0.05 comparing WT CCI and WT sham, #
p,0.05 comparing IGF-1 Tg CCI and IGF-1Tg sham, and ! p,0.05
comparing IGF-1Tg CCI to WT CCI.
doi:10.1371/journal.pone.0067204.g008
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evidence for the beneficial effects of CNS-derived IGF-1 for TBI
treatment as well as the usefulness this cell-specific, gene-based
approach in delivering IGF-1 specifically to vulnerable brain
regions. Delivering IGF-1 through reactive astrocytes targeted
IGF-1 overexpression to the damaged hippocampus, producing a
progressive increase in IGF-1 over 72 h which led to activation of
the Akt pro-survival pathway and reduced hippocampal neuron
loss in multiple regions after both moderate and severe contusion
TBI. Importantly, hippocampal neuroprotection was coupled with
improved cognitive and motor function. This strategy may be
suitable for delivery of IGF-1 and other endogenous molecules in
other CNS disorders in which astrocytosis is a prominent
pathological feature.
Supporting Information
Figure S1 Schematic representation of conditional
overexpression strategy. The M-1 mouse line carries a
transgene for producing astrocyte-specific tetracycline transacti-
vator protein (tTA), where the GFAP promoter (pGFAP) is linked
to tTA. M-2 mice have a tetracycline responsive element (TRE)
upstream of a CMV-hIGF-1 insert. By crossing M-1 and M-2 lines
mice were generated that carry both transgenes (IGF-1Tg) in
which tTA protein expressed only in GFAP-positive astrocytes
binds to TRE to induce IGF-1 transgene expression. When
doxycycline (DOX) is present it tightly binds to tTA, suppressing
IGF-1 expression.
(TIF)
Figure S2 Continuous Doxycycline (Dox) induced sup-
pression of IGF-1 overexpression eliminates enhanced
astrocyte hypertrophy in IGF-1Tg mice after brain
injury. WT and IGF-1Tg mice were maintained on Dox-
supplemented chow to suppress IGF-1 overexpression during the
entire period of study. At 72 h after moderate brain injury, IGF-1
immunostaining in IGF-1Tg mice was comparable to that in WT
mice indicating that IGF-1 overexpression was blocked by Dox
(top panels). Injury-induced reactive astrocytosis was also compa-
rable in WT mice and IGF-1Tg mice (middle panels). Boxed areas
are magnified in the bottom panels to illustrate similar GFAP
immunoreactivity in hypertrophied astrocytes in the hippocampus
ipsilateral to the impact. Scale bar = 100 mm (IGF-1 and GFAP
panels) and 50 mm (high magnification lower panel).
(TIF)
Figure S3 Akt phosphorylation in IGF-1Tg mice is
associated with neurons as well as astrocytes. Upper
panels show representative confocal images from the ipsilateral
hippocampus (CA-3 area shown) of brain-injured IGF-1Tg mice
showing co-localization (arrows) of p-Akt (green) with the neuronal
marker NeuN (red). Not all neurons expressed p-Akt (arrowheads).
Lower panels show the dentate gyrus area where a subset of
GFAP-positive (red) astrocytes clearly expressed p-Akt (green)
(arrows), while many did not (arrowheads). DH: dentate hilus, GL:
granule layer. Scale bar = 100 mm.
(TIF)
Figure S4 IGF-1 overexpression did not change total Akt
(T-Akt) protein levels after brain injury. Representative
western blot image showing total Akt (T-Akt) and actin from
hippocampal homogenates of wild-type (WT) and IGF-1Tg mice
at 72 h after 1.0 mm controlled cortical impact (CCI) or sham (Sh)
injury.
(TIF)
Figure S5 IGF-1 overexpression promoted hilar neuron
survival at 72 h after moderate brain injury. Nissl staining
(Cresyl violet dye) was performed to detect surviving neurons in
the hippocampus (HP). At 72 h after moderate (0.5 mm depth)
injury, the hilus of the dentate gyrus (DG) in wildtype (WT) mice
exhibited partial neuronal loss. The density and morphology of
Nissl-stained hilar neurons (arrowheads) was improved in brain-
injured IGF-1 transgenic (IGF-1Tg) relative to WT mice. Scale
bars = 500 mm (upper panel) and 100 mm (lower panel).
(TIF)
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